Epstein–Barr virus (EBV) is a near-universal human herpesvirus increasingly recognized as a modifier in several autoimmune diseases, notably multiple sclerosis (MS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Shared pathogenic mechanisms include the effects of latent viral proteins, molecular mimicry, infection and persistence within autoreactive B-cells, and dysregulated type 1 interferon (IFN-1) responses. Disease-specific outcomes reflect differences in tissue localization of infected cells, patterns of viral reactivation, and host genetic background. Understanding these shared and selective vulnerabilities may inform preventive and therapeutic approaches for EBV-associated autoimmunity.
Epstein–Barr virus (EBV), also called human herpesvirus 4, infects the majority of adults worldwide. Primary infection is often asymptomatic in early childhood but can present as infectious mononucleosis (IM) when delayed into adolescence or young adulthood. EBV establishes life-long latency in B-lymphocytes, maintaining an episomal genome and expressing a restricted set of latent genes and noncoding RNAs. Four latency programs (0, I, II, III) are defined by distinct gene expression patterns: latency 0 (EBERs only), latency I (EBERs and EBNA1), latency II (EBERs, EBNA1, LMP1, LMP2), and latency III (broader EBNA and LMP expression).
The virus’s capacity to persist and periodically reactivate, together with specific latent gene products and microRNAs, underpins its potential to perturb immune tolerance. Epidemiologic data, including large longitudinal cohorts, highlight a strong association between EBV infection and subsequent MS risk, while EBV associations with SLE and RA are supported by multiple mechanistic and serological observations. Importantly, EBV infection alone is not sufficient to cause autoimmune disease; it acts within a network of genetic, environmental, and immunological factors.
Latent viral proteins and noncoding RNAs expressed by EBV interact with host immunity in ways that can promote autoimmunity across diseases.
EBNA1 is uniquely persistent across latency states and elicits elevated antibody responses in MS, SLE, and RA. EBNA1 limits presentation of its peptides yet provokes T-cell–independent antibody responses and can drive epitope spreading. Cross-reactive EBNA1-specific CD4+ T-cells have been linked to recognition of neural antigens implicated in MS.
LMP1 functions as a CD40 mimic, aggregating constitutively and driving B-cell activation, germinal center-like responses, upregulation of activation-induced cytidine deaminase (AID), class switching, and survival of autoreactive B-cells. Through ligand-independent signaling, LMP1 can sustain B-cell activation and promote autoantibody production.
LMP2A enhances antigen presentation and modulates BCR–TLR signaling, lowering activation thresholds and facilitating survival and plasma cell differentiation of autoreactive clones. LMP2A has been implicated in promoting anti-Sm responses and enhancing TLR sensitivity in experimental models.
EBNA2 is a key transcriptional activator during latency that regulates viral promoters and interacts with host transcription factors. EBNA2 binding overlaps many genomic loci linked to autoimmune risk and may influence NF-κB–related inflammatory pathways.
EBV proteins display short linear mimicry of host motifs, providing a mechanism for breaking tolerance while minimizing fitness costs to the virus. Although mimicry is a shared mechanism, the targeted host proteins differ by disease: myelin and glial proteins in MS, multiple lupus autoantigens in SLE, and synovial and collagen-related proteins in RA. Latent proteins appear particularly enriched for mimicry, and latency increases exposure of cross-reactive epitopes over time.
Naïve B-cell repertoires include autoreactive clones normally constrained by central and peripheral tolerance. EBV infection can rescue these clones by promoting proliferation, apoptosis resistance, and persistence as latently infected memory B-cells that function as potent antigen-presenting cells. These cells sustain autoreactive CD4+ T-cell help, promote class-switching and autoantibody generation, and can drive complement-activating IgM responses and extrafollicular immunoglobulin production.
EBV nucleic acids and proteins activate pattern recognition receptors (TLRs, RIG-I–like receptors, cGAS–STING), triggering IFN-1 release. Dysregulated IFN-1 signaling contributes to systemic inflammation and organ damage in autoimmune disease. TLR polymorphisms modulate disease associations, and clinical trials targeting IFN pathways—particularly in SLE—underscore the pathological relevance of IFN-1 in EBV-related autoimmunity.
While EBV-driven mechanisms overlap across diseases, the phenotype depends on where and how infected cells and immune responses are localized and regulated.
In MS, evidence points to CNS-compartmentalized immune responses, formation of meningeal tertiary lymphoid structures, and molecular mimicry between EBV epitopes (notably EBNA1) and neural antigens such as GlialCAM, myelin basic protein, αB-crystallin, and anoctamin-2. These localized processes help explain CNS-targeted neuroinflammation.
In SLE, EBV contributes to systemic autoimmunity via mimicry with multiple lupus-associated autoantigens (Sm, Ro, C1q, dsDNA), recurrent viral reactivation, and IFN-driven multi-organ inflammation. SLE is associated with higher systemic viral loads and diverse cross-reactive immune responses.
In RA, persistence of EBV within synovial tissue, formation of synovial ectopic lymphoid structures, promotion of anti-citrullinated protein antibody responses, and dysregulated proinflammatory cytokines are implicated. EBV latent proteins such as EBNA1, EBNA2, and viral IL-10 homologs have been linked to synovial immune activation.
Other modifiers of disease outcome include timing of primary infection—delayed infection with IM is associated with increased MS risk—and environmental or demographic factors that may influence infection timing or immune responses.
Host genetic variation, especially in HLA alleles, modulates susceptibility to EBV-associated autoimmunity by shaping antigen presentation and T-cell repertoires. HLA influences which viral and self-peptides are presented, the effectiveness of viral control, and the propensity for autoreactive T-cell activation. Interactions between EBV proteins (e.g., EBNA2 binding at autoimmune risk loci) and HLA-defined antigen presentation help determine disease specificity and severity. Details on specific HLA associations were discussed in the source but comprehensive allele-by-allele data are not reproduced here.
EBV does not act as a singular, uniform cause of autoimmunity but rather as a context-dependent immunological modifier. Shared mechanisms—latent protein effects, molecular mimicry, infection of autoreactive B-cells, and IFN-1 dysregulation—combine with tissue-specific viral persistence, timing of infection, and HLA-defined genetic background to produce diverse autoimmune phenotypes such as MS, SLE, and RA. Clarifying these mechanisms in detail may support targeted preventive and therapeutic strategies for EBV-associated autoimmune diseases.